Intelligence · Clinical Pipeline
AXIM Biotechnologies Pipeline
All ClinicalTrials.gov programs at AXIM Biotechnologies — phase, modality, and trial IDs.
- Programs
- 12
Quick answer
AXIM Biotechnologies has 12 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
ANAKINRA
AXIM BIOTECHNOLOGIES, INC.
Hyperinflammation, Sepsis
1 trial -
Anti-GD2-800CW
AXIM BIOTECHNOLOGIES, INC.
Neuroblastoma
1 trial -
BRIGATINIB, Alunbrig 180 mg film-coated tablets, Alunbrig 90 mg film-coated tablets, Alunbrig 30 mg film-coated tablets
AXIM BIOTECHNOLOGIES, INC.
Anaplastic Large Cell Lymphoma (ALCL), Inflammatory Myofibroblastic Tumors (IMT), Other solid tumors
1 trial -
Etoposide 20 mg/ml Concentrate for Solution for Infusion, Sodium Chloride 0.9% Intravenous Infusion BP, Vincristine Sulfate 1 mg/ml Solution for Injection or Infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Human Albumin Baxalta 50 g/l Solution for Infusion, Cyclophosphamide 1000 mg Powder for Solution for Injection or Infusion, Qarziba 4.5 mg/mL concentrate for solution for infusion, Dacarbazine Lipomed 200 mg powder for solu
AXIM BIOTECHNOLOGIES, INC.
Neuroblastoma
1 trial -
IOBENGUANE (123I) , 68Ga-SSO120
AXIM BIOTECHNOLOGIES, INC.
neuroblastoma
1 trial -
IOBENGUANE (123I) , [18F]meta-fluorobenzylguanidine
AXIM BIOTECHNOLOGIES, INC.
(suspision on) Neuroblastoma
1 trial -
Jakavi 5 mg tablets, Venetoclax, Jakavi 20 mg tablets, Venetoclax, Jakavi 10 mg tablets, Venetoclax, Venetoclax, Venetoclax, Venetoclax, Jakavi 15 mg tablets
AXIM BIOTECHNOLOGIES, INC.
Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
1 trial -
MB-huCART19.1
AXIM BIOTECHNOLOGIES, INC.
B-cell precursor ALL, B-cell Non Hodgkin Lymphoma
1 trial -
ONC201, Paxalisib
AXIM BIOTECHNOLOGIES, INC.
Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs)
1 trial -
Quizartinib
AXIM BIOTECHNOLOGIES, INC.
newly diagnosed pediatric FLT3-ITD positive and NPM1 wild-type AML
1 trial -
SPRYCEL 70 mg film-coated tablets, Venetoclax, SPRYCEL 100 mg film-coated tablets, Venetoclax, SPRYCEL 20 mg film-coated tablets, Venetoclax, SPRYCEL 50 mg film-coated tablets, Venetoclax, Venetoclax, Venetoclax, SPRYCEL 10 mg/mL powder for oral suspension
AXIM BIOTECHNOLOGIES, INC.
Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
1 trial -
Tovorafenib, Tovorafenib
AXIM BIOTECHNOLOGIES, INC.
craniopharyngioma
1 trial
Frequently asked questions
How many pipeline programs does AXIM Biotechnologies have?
12 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs